<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00062127</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02537</org_study_id>
    <secondary_id>12044B</secondary_id>
    <secondary_id>U01CA069852</secondary_id>
    <secondary_id>CDR0000304517</secondary_id>
    <nct_id>NCT00062127</nct_id>
  </id_info>
  <brief_title>Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Pharmacokinetic Interaction Study of Irinotecan (NSC616348) and Thalidomide (NSC66847) in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in&#xD;
      chemotherapy such as irinotecan use different ways to stop tumor cells from dividing so they&#xD;
      stop growing or die. Combining thalidomide with irinotecan may kill more tumor cells. This&#xD;
      randomized phase I trial is studying the side effects and best way to give irinotecan and&#xD;
      thalidomide in treating patients with metastatic or unresectable solid tumors&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine whether thalidomide alters the pharmacokinetics of irinotecan in patients with&#xD;
      advanced solid tumors.&#xD;
&#xD;
      II. Determine whether irinotecan alters the pharmacokinetics of thalidomide in these&#xD;
      patients.&#xD;
&#xD;
      III. Determine the toxicity of this regimen in these patients. IV. Determine the observed&#xD;
      antitumor response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      Arm I: Patients receive irinotecan IV over 90 minutes on days 1 and 22 and oral thalidomide&#xD;
      once daily on days 15-28.&#xD;
&#xD;
      Arm II: Patients receive irinotecan as in arm I and oral thalidomide once daily on days -6 to&#xD;
      7.&#xD;
&#xD;
      All patients undergo disease re-evaluation at 6 weeks. Patients with stable or responsive&#xD;
      disease may receive additional courses comprising irinotecan IV on day 1 and oral thalidomide&#xD;
      once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression&#xD;
      or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of thalidomide on irinotecan hydrochloride pharmacokinetics</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of irinotecan hydrochloride on thalidomide pharmacokinetics</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 and 24 and 168 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade 3 or greater toxicities assessed using NCI CTC version 2.0</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be summarized and analyzed using descriptive statistics. Exact 90% confidence intervals using the binomial distribution will be derived.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response assessed using RECIST criteria</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be summarized and analyzed using descriptive statistics. Exact 90% confidence intervals using the binomial distribution will be derived.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I (irinotecan hydrochloride and thalidomide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive irinotecan IV over 90 minutes on days 1 and 22 and oral thalidomide once daily on days 15-28. All patients undergo disease re-evaluation at 6 weeks. Patients with stable or responsive disease may receive additional courses comprising irinotecan IV on day 1 and oral thalidomide once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (irinotecan hydrochloride and thalidomide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive irinotecan as in arm I and oral thalidomide once daily on days -6 to 7. All patients undergo disease re-evaluation at 6 weeks. Patients with stable or responsive disease may receive additional courses comprising irinotecan IV on day 1 and oral thalidomide once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (irinotecan hydrochloride and thalidomide)</arm_group_label>
    <arm_group_label>Arm II (irinotecan hydrochloride and thalidomide)</arm_group_label>
    <other_name>Campto</other_name>
    <other_name>Camptosar</other_name>
    <other_name>CPT-11</other_name>
    <other_name>irinotecan</other_name>
    <other_name>U-101440E</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I (irinotecan hydrochloride and thalidomide)</arm_group_label>
    <arm_group_label>Arm II (irinotecan hydrochloride and thalidomide)</arm_group_label>
    <other_name>Kevadon</other_name>
    <other_name>Synovir</other_name>
    <other_name>THAL</other_name>
    <other_name>Thalomid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (irinotecan hydrochloride and thalidomide)</arm_group_label>
    <arm_group_label>Arm II (irinotecan hydrochloride and thalidomide)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed malignant solid tumor&#xD;
&#xD;
               -  Metastatic or unresectable&#xD;
&#xD;
               -  Standard curative or palliative therapy is no longer effective or does not exist&#xD;
&#xD;
          -  Measurable or assessable disease&#xD;
&#xD;
          -  No uncontrolled brain metastases&#xD;
&#xD;
               -  Patients with brain metastases are eligible provided the following are true:&#xD;
&#xD;
                    -  Stable neurologic status&#xD;
&#xD;
                    -  At least 4 weeks since prior steroids or anticonvulsants&#xD;
&#xD;
                    -  No neurologic dysfunction that would confound evaluation&#xD;
&#xD;
          -  Performance status - Karnofsky 70-100%&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No history of inflammatory bowel disease requiring therapy&#xD;
&#xD;
          -  No chronic diarrhea syndromes&#xD;
&#xD;
          -  No paralytic ileus&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile female patients must use 2 forms of effective contraception, including 1&#xD;
             highly effective method, for at least 4 weeks before, during, and for 4 weeks after&#xD;
             study participation&#xD;
&#xD;
          -  Male patients must use effective barrier contraception during and for 4 weeks after&#xD;
             study participation&#xD;
&#xD;
          -  No prior allergic reaction attributed to compounds of similar chemical or biological&#xD;
             composition to study drugs&#xD;
&#xD;
          -  No uncontrolled seizure disorder&#xD;
&#xD;
          -  No other concurrent uncontrolled illness that would preclude study participation&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No significant traumatic injury within the past 28 days&#xD;
&#xD;
          -  No serious, nonhealing wounds or ulcers&#xD;
&#xD;
          -  No bone fractures&#xD;
&#xD;
          -  No preexisting peripheral neuropathy grade 2 or greater&#xD;
&#xD;
          -  At least 4 weeks since prior biologic therapy&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  More than 28 days since prior major surgical procedure or open biopsy&#xD;
&#xD;
          -  At least 4 weeks since prior investigational therapy&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent investigational or commercial agents or therapies for the&#xD;
             malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Ratain</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>June 5, 2003</study_first_submitted>
  <study_first_submitted_qc>June 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2003</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

